Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Go back to Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.02 -0.61 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.63 | 52 Week High | $45.58 | |||
| Open | $50.19 | 52 Week Low | $37.82 | |||
| Day High | $50.45 | P/E | N/A | |||
| Day Low | $49.91 | EPS | $0.00 | |||
| Volume | 3,614,140 | |||||
| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.02 -0.61 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.63 | 52 Week High | $45.58 | |||
| Open | $50.19 | 52 Week Low | $37.82 | |||
| Day High | $50.45 | P/E | N/A | |||
| Day Low | $49.91 | EPS | $0.00 | |||
| Volume | 3,614,140 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 29.85 -0.26 (0.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.11 | 52 Week High | $37.39 | |||
| Open | $30.00 | 52 Week Low | $28.25 | |||
| Day High | $30.09 | P/E | 18.09 | |||
| Day Low | $29.69 | EPS | $1.65 | |||
| Volume | 22,211,433 | |||||



